Changeflow GovPing Pharma & Drug Safety CD38 Antibody Variant Improves Manufacturing Yield
Routine Rule Added Final

CD38 Antibody Variant Improves Manufacturing Yield

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

USPTO granted patent US12600790B2 to Vivasor, Inc. covering a variant anti-CD38 IgG antibody with improved manufacturing yield and a mutated light chain that reduces cleavage heterogeneity. The patent contains 19 claims and is classified under C07K 16/2878 and related CPC codes.

What changed

USPTO granted patent US12600790B2 to Vivasor, Inc. for an anti-CD38 IgG antibody variant with improved manufacturing yield through reduced cleavage heterogeneity. The patent covers the antibody sequence modifications and production methods.

Companies developing CD38-targeted therapeutics should review the claims for potential licensing needs or freedom-to-operate concerns. The 19 granted claims establish enforceable IP rights in the antibody therapeutics space.

What to do next

  1. Review patent claims for freedom-to-operate implications
  2. Assess licensing requirements for CD38 antibody development
  3. Monitor for related patent publications

Archived snapshot

Apr 14, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Variant antibody that binds CD38

Grant US12600790B2 Kind: B2 Apr 14, 2026

Assignee

Vivasor, Inc.

Inventors

Barbara A. Swanson, Heyue Zhou, Jian Cao

Abstract

The present disclosure provides anti-CD38 IgG class antibody having improved ability to be manufactured at higher yields compared to the parent antibody having the original wild type sequence. The present disclosure provides a mutated antibody light chain that reduces cleavage heterogeneity for improved production of a homogeneous population of antibody light chains.

CPC Classifications

C07K 16/2878 C07K 2317/21 C07K 2317/55 C07K 2317/565 C07K 2317/24 C07K 2317/92 C07K 16/2896 A61K 2039/505

Filing Date

2020-12-18

Application No.

17127766

Claims

19

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
US12600790B2

Who this affects

Applies to
Pharmaceutical companies Medical device makers
Industry sector
3254.1 Biotechnology
Activity scope
Patent grant Intellectual property
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!